Trastuzumab deruxtecan (T-DXd; DS-8201) in patients with HER2-low, advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma: Results of the exploratory cohorts in the phase II, multicenter, open-label DESTINY-Gastric01 study-MedSci.cn

Trastuzumab deruxtecan (T-DXd; DS-8201) in patients with HER2-low, advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma: Results of the exploratory cohorts in the phase II, multicenter, open-label DESTINY-Gastric01 study

Yamaguchi, K; Bang, YJ; Iwasa, S; Sugimoto, N; Ryu, MH; Sakai, D; Chung, HC; Kawakami, H; Yabusaki, H; Lee, J; Saito, K; Kawaguchi, Y; Kamio, T; Kojima, A; Sugihara, M; Shitara, K

ANNALS OF ONCOLOGY, 2020; 31 (): S899

科室
- - 订阅+
  - 更多科室
工具
服务